Unveiling the Role of Pharmacy Benefit Managers (PBMs)

Key Takeaways

• PBMs negotiate drug price discounts for insurance companies.
• Profits come from drug upcharges and rebate portions.
• The industry is marked by consolidation and mergers.
• CVS Health, Cigna, and UnitedHealth are major PBM players.
• Lack of transparency in PBM models draws criticism.

Get personalized, AI-powered answers built on 27+ years of trusted expertise.

ASK

Understanding the Pharmacy Benefit Management (PBM) Industry

The pharmacy benefit management (PBM) industry is a group of companies that serve as the middlemen between insurance companies, pharmacies, and drug manufacturers. PBMs are responsible for securing lower drug costs for insurers and insurance companies.

They accomplish this by negotiating with pharmacies and drug manufacturers. The discounts are then passed on to the insurance companies. Profits are generated through a slight up-charging of drugs or by retaining portions of rebates. Major players in the PBM market include CVS Health, Cigna, and UnitedHealth Group. One of the main criticisms of the market is a lack of transparency about rebates, discounts, and savings.

The Role of PBMs in the Healthcare System

Insurance is a multilayered business with many players serving a variety of interests and purposes, just like other subsectors of the economy. Insurance companies aren’t the only entities that operate in this industry. It also includes reinsurers, underwriters, and pharmacy benefit management companies.

Insurance companies rely on PBMs to manage costs, making them the middleman. PBMs leverage their role by negotiating discounts with drug manufacturers for insurance companies in exchange for putting the manufacturer’s drugs in front of millions of customers. These companies also negotiate contracts with pharmacies to create networks of retail pharmacies for drug distribution.

PBMs exploit several revenue streams. They charge service fees for:

• Negotiating with pharmacies, insurance companies, and drug manufacturers
• Processing prescriptions
• Operating mail-order pharmacies

Contracts with the largest insurance companies can quickly change the prospects of a PBM, giving it huge power when negotiating with drug manufacturers and pharmacies. It should come as no surprise that competition is fierce, with PBMs working to optimally position themselves for contract negotiation with insurance companies.

_Source: _The Wall Street Journal

Key Challenges and Trends in the PBM Industry

The cost of drugs has exploded over the years, leading insurance companies to rely heavily on PBMs to control and reduce their liabilities. The industry has seen increased competition among PBMs as well as consolidation. Mergers and acquisitions (M&A) allow PBMs to increase in size and boost their negotiating power.

There has also been consolidation between pharmacies and PBMs due to the inherent synergies between them. Rite Aid bought out EnvisionRX in 2015 and CVS Caremark has long had direct access to CVS’s retail pharmacy network.

$449.12 billion

The amount brought in by the global pharmacy benefit management industry in revenues each year. This amount is expected to reach $735.05 billion by 2027.

Controversies and Concerns Surrounding PBMs

As the sheer nature of the business likely implies, PBMs are common targets of lawsuits and government scrutiny. As third-party negotiators, many of their business practices are opaque so PBMs haven’t always disclosed rebates, discounts, itemized billing statements, or the percentage of savings passed on to insurers.

What Are the 3 Largest Pharmacy Benefit Managers?

Drug Channels tags OptumRX, Express Scripts, and Caremark as the big three. OptumRX is run and owned by UnitedHealth Group. Cigna is at the helm of Express Scripts, and Caremark is owned and run by CVS Health.

How Do PBMs Affect Medicare?

The Pharmaceutical Care Management Association has estimated that PBMs will save Medicare Part D and its beneficiaries more than $437 billion over 10 years ending in 2032.

The Bottom Line

State legislatures have been pushing for greater transparency and disclosure provisions to better regulate PBMs, while also pressuring the industry to adopt fiduciary duty standards, requiring PBMs to act in the best interest of insurers and insurance plans, similar to the legal obligation of financial advisors toward their clients.

Together, these efforts signal potential regulatory changes that could affect the future profitability of the PBM industry.